Aerovate Therapeutics (AVTE) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

Aerovate Therapeutics Revenue Highlights


00

Aerovate Therapeutics Revenue by Period


Aerovate Therapeutics Revenue by Year

DateRevenueChange
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--

Aerovate Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Aerovate Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$136.00K100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

Aerovate Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Aerovate Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
ADAGAdagene$18.11M$833.34K
OPTOpthea$108.41K$61.27K
ANEBAnebulo Pharmaceuticals--
RZLTRezolute--
ANTXAN2 Therapeutics--
AVTEAerovate Therapeutics--
ACRVAcrivon Therapeutics--
MLYSMineralys Therapeutics--

AVTE Revenue FAQ


Aerovate Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. AVTE's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

Aerovate Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). AVTE's quarterly revenue for Q4 2023 was $136K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).

Aerovate Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.